Form 8-K - Current report:
SEC Accession No. 0001104659-22-047977
Filing Date
2022-04-21
Accepted
2022-04-20 18:45:29
Documents
14
Period of Report
2022-04-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2212593d1_8k.htm   iXBRL 8-K 35941
2 EXHIBIT 99.1 tm2212593d1_ex99-1.htm EX-99.1 362423
  Complete submission text file 0001104659-22-047977.txt   650916

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrk-20220420.xsd EX-101.SCH 4152
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mrk-20220420_def.xml EX-101.DEF 28239
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrk-20220420_lab.xml EX-101.LAB 38353
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrk-20220420_pre.xml EX-101.PRE 26849
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2212593d1_8k_htm.xml XML 7850
Mailing Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033
Business Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 908-740-4000
Merck & Co., Inc. (Filer) CIK: 0000310158 (see all company filings)

EIN.: 221918501 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-06571 | Film No.: 22839259
SIC: 2834 Pharmaceutical Preparations